• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed

    2/8/21 1:47:15 PM ET
    $MGLN
    Hospital/Nursing Management
    Health Care
    Get the next $MGLN alert in real time by email
    SC 13D 1 tm215743d1_sc13d.htm SC 13D

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D. C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    MAGELLAN HEALTH, INC.

    (Name of Issuer)

     

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

     

    559079207

    (CUSIP Number of Class of Securities)

     

    Alec N. Litowitz

    Magnetar Capital LLC

    1603 Orrington Ave.

    Evanston, Illinois 60201

    (847) 905-4400 

    (Name, Address and Telephone Number of Person Authorized
    to Receive Notices and Communications)

     

    January 29, 2021

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a Statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this Schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7(b) for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 559079207 SCHEDULE 13D Page 2 of 10

     

    1.

    NAME OF REPORTING PERSON:

     

    Magnetar Financial LLC

     

    2. 

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)   ¨

    (b)   x

    3. SEC USE ONLY
    4.

    SOURCE OF FUNDS

     

    OO

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨
    6. 

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    7. 

    SOLE VOTING POWER

    0

    BENEFICIALLY

    OWNED BY

    8.

    SHARED VOTING POWER

    1,373,642

    EACH REPORTING

    PERSON

    9. 

    SOLE DISPOSITIVE POWER

    0

    WITH 10.

    SHARED DISPOSITIVE POWER

    1,373,642

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,373,642

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    5.31%

    14. 

    TYPE OF REPORTING PERSON

     

    IA; OO

     

     

     

     

    CUSIP No. 559079207 SCHEDULE 13D Page 3 of 10

     

    1.

    NAME OF REPORTING PERSON:

     

    Magnetar Capital Partners LP

     

    2. 

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)    ¨

    (b)   x

    3. SEC USE ONLY
    4.

    SOURCE OF FUNDS

     

    OO

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨
    6. 

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    7. 

    SOLE VOTING POWER

    0

    BENEFICIALLY

    OWNED BY

    8.

    SHARED VOTING POWER

    1,373,642

    EACH REPORTING

    PERSON

    9. 

    SOLE DISPOSITIVE POWER

    0

    WITH 10.

    SHARED DISPOSITIVE POWER

    1,373,642

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,373,642

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

    ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    5.31%

    14. 

    TYPE OF REPORTING PERSON

     

    HC; OO

     

     

     

     

    CUSIP No. 559079207 SCHEDULE 13D Page 4 of 10

     

    1.

    NAME OF REPORTING PERSON:

     

    Supernova Management LLC

     

    2. 

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)    ¨

    (b)   x

    3. SEC USE ONLY
    4.

    SOURCE OF FUNDS

     

    OO

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨
    6. 

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    7. 

    SOLE VOTING POWER

    0

    BENEFICIALLY

    OWNED BY

    8.

    SHARED VOTING POWER

    1,373,642

    EACH REPORTING

    PERSON

    9. 

    SOLE DISPOSITIVE POWER

    0

    WITH 10.

    SHARED DISPOSITIVE POWER

    1,373,642

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,373,642

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

    ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    5.31%

    14. 

    TYPE OF REPORTING PERSON

     

    HC; OO

     

     

     

     

    CUSIP No. 559079207 SCHEDULE 13D Page 5 of 10

     

    1.

    NAME OF REPORTING PERSON:

     

    Alec N. Litowitz 

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

    (b)       x

    3.

    SEC USE ONLY

     

    4.

    SOURCE OF FUNDS

     

    OO

    5.

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)         ¨

     

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF

    SHARES

    7.

    SOLE VOTING POWER

    0

    BENEFICIALLY

    OWNED BY

    8.

    SHARED VOTING POWER

    1,373,642

    EACH REPORTING

    PERSON

    9.

    SOLE DISPOSITIVE POWER

    0

    WITH

    10.

    SHARED DISPOSITIVE POWER

    1,373,642

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,373,642

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    5.31%

    14.

    TYPE OF REPORTING PERSON

     

    HC; IN

     

     

     

     

     

    SCHEDULE 13D

     

    item 1.security and issuer

     

    This Schedule 13D (this “Statement”) relates to the common stock, par value $0.01 (the “Shares”), of Magellan Health, Inc., a company incorporated in Delaware (the “Company”). The principal executive offices of the Company is 4801 E. Washington Street, Phoenix, AZ, 85034, United States.

     

    Item 2.identity and background

     

    (a)       The persons filing this Statement are Magnetar Financial LLC, a Delaware limited liability company (“Magnetar Financial”), Magnetar Capital Partners LP, a Delaware limited partnership (“Magnetar Capital Partners”), Supernova Management LLC, a Delaware limited liability company (“Supernova Management”), and Alec N. Litowitz (“Mr. Litowitz”) (collectively, the “Reporting Persons”).

     

    This Statement relates to Shares held for the accounts of each of (i) Magnetar PRA Master Fund Ltd, a Cayman Islands exempted company (“PRA Master Fund”), (ii) Magnetar Constellation Fund II-PRA LP, a Delaware limited partnership (“Constellation Fund”), and (iii) Magnetar Systematic Multi-Strategy Master Fund Ltd, a Cayman Islands exempted company, (“Systematic Master Fund”), collectively (the “Funds”).

     

    Magnetar Financial is a Securities and Exchange Commission (“SEC”) registered investment adviser under Section 203 of the Investment Advisers Act of 1940, as amended, and manager of investment funds and managed accounts. Magnetar Financial serves as investment adviser to each of the Funds. In such capacity, Magnetar Financial exercises voting and investment power over the Shares held for the accounts of each of the Funds. Magnetar Capital Partners serves as the sole member and parent holding company of Magnetar Financial. Supernova Management is the general partner of Magnetar Capital Partners. The manager of Supernova Management is Mr. Litowitz.

     

    (b)       The business address of each of the Reporting Persons is 1603 Orrington Avenue, 13th Floor, Evanston, Illinois 60201.

     

    (c)       Each of the Funds is a private investment fund; Magnetar Financial is a privately-held SEC registered investment adviser and manager of investment funds and managed accounts; Magnetar Capital Partners is a privately-held limited partnership and serves as the sole member and parent holding company of Magnetar Financial; Supernova Management is a privately-held limited liability company and is the general partner of Magnetar Capital Partners; and Mr. Litowitz is a citizen of the United States of America, manager of Supernova Management and Chief Executive Officer of Magnetar Financial.

     

    (d)       None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e)       None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such Reporting Person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f)       Magnetar Financial is a Delaware limited liability company. Magnetar Capital Partners is a Delaware limited partnership. Supernova Management is a Delaware limited liability company. Mr. Litowitz is a citizen of the United States of America.

     

     

     

     

    Item 3.source and amount of funds or other consideration

     

    The aggregate amount of funds used by the Reporting Persons in purchasing the 1,373,642 Shares reported herein on behalf of the Funds have come directly from the assets of the Funds, which may at any given time, have included margin loans made by brokerage firms in the ordinary course of business. The aggregate amount of funds used by the Reporting Persons in purchasing the Shares on behalf of the Funds was $129,082,992 (excluding commissions and other execution-related costs).

     

    ITEM 4.PURPOSE OF TRANSACTION

     

    The Reporting Persons acquired the 1,373,642 Shares reported herein on behalf of the Funds after the public announcement of the Merger Agreement (as defined below) for purposes of receiving the merger consideration described below upon consummation of the Merger (as described below).

     

    The 6,295 Shares reported herein were acquired in the ordinary course of business on behalf of certain clients of Magnetar Financial in an another strategy unrelated to risk arbitrage to cover its short positions described in Item 6.

     

    Each of the Reporting Persons reserves the right to acquire additional securities of the Company in the open market, in privately negotiated transactions, or otherwise, to dispose of all or a portion of the Shares and/or other securities reported in this Statement, or to change their intention with respect to any or all of the matters referred to in this Item 4.

     

    Other than as described above in this Item 4, the Reporting Persons do not have any plans or proposals that relate to, or would result in, any actions or events specified in clauses (a) through (j) of Item 4 to Schedule 13D.

     

    ITEM 5.INTEREST IN SECURITIES OF THE ISSUER

     

    The Company reported in their Form 8-K filed on January 4, 2021 that 25,887,446 Shares were issued and outstanding as of December 28, 2020.

     

    (a)               As of the close of business February 5, 2021, each of the Reporting Persons may have been deemed to have beneficial ownership of 1,373,642 Shares, which consisted of (i) 555,796 Shares held for the benefit of PRA Master Fund, (ii) 682,563 Shares held for the benefit of Constellation Fund; and (iii) 135,283 Shares held for the benefit of Systematic Master Fund, and all such Shares represented beneficial ownership of approximately 5.31% of the Shares.

     

    (b)               As of the close of business February 5, 2021, each of the Reporting Persons may have been deemed to share the power to vote and direct the disposition of 1,373,642 Shares, which consisted of (i) 555,796 Shares held for the benefit of PRA Master Fund, (ii) 682,563 Shares held for the benefit of Constellation Fund; and (iii) 135,283 Shares held for the benefit of Systematic Master Fund, and all such Shares represented beneficial ownership of approximately 5.31% of the Shares.

     

     

     

     

    (c)               Except as set forth on Schedule A attached hereto and Item 6, the Funds had no transactions in the Shares during the 60 days preceding the date of filing of this Statement. All of the transactions set forth on Schedule A attached hereto were effected in the ordinary course of business of Magnetar Financial for the accounts of each of the Funds. The transactions in the Shares set forth on Schedule A were effected in open market transactions on NASDAQ and various other trading markets.

     

    As disclosed by the Company in the Form 8-K filed with the SEC on January 4, 2021:

     

    On January 4, 2021, Magellan Health, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Centene Corporation, a Delaware corporation (“Centene”), and Mayflower Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Centene (“Merger Sub”). Among other things, the Merger Agreement provides, subject to the satisfaction or, where permissible, waiver of the conditions to closing set forth therein, for the merger of Merger Sub with and into the Company (the “Merger”), with the Company continuing as the surviving corporation of the Merger and a wholly owned subsidiary of Centene (the “Surviving Corporation”). Each capitalized term used herein but not otherwise defined has the meaning given to it in the Merger Agreement.

     

    On the terms and subject to the conditions set forth in the Merger Agreement, at the effective time of the Merger (the “Effective Time”), each share of common stock, par value $0.01 per share, of the Company (the “Company Common Stock”) issued and outstanding immediately prior to the Effective Time (other than any shares of Company Common Stock owned by the Company, any shares of Company Common Stock owned by Centene or Merger Sub, any shares of Company Common Stock as to which appraisal rights have been properly exercised, and any shares of Company Common Stock underlying restricted stock awards of the Company) will be automatically canceled and converted into the right to receive $95.00 in cash, without interest (the “Merger Consideration”).

     

    (d)       No other person is known by the Reporting Persons to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any Shares that are beneficially owned by the Reporting Persons.

     

    ITEM 6.contracts, arrangements, understandings or relationships with respect to the securities of the issuer

     

    Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the Reporting Persons have entered into an agreement with respect to the joint filing of this Statement, and any amendment or amendments hereto.

     

    A client of Magnetar Financial has entered into a total return swap agreement giving it economic exposure to the Company.

     

     

     

     

    Magnetar Asset Management LLC (“Magnetar Asset Management”) is an SEC registered investment adviser and an affiliate of Magnetar Financial. Magnetar Capital Partners serves as the sole member and parent holding company of Magnetar Asset Management. Certain clients of Magnetar Asset Management have entered into total return swap agreements giving them economic exposure to the Company.

     

    The 26,381 Shares described herein that were sold short in the ordinary course of business on behalf of certain clients of Magnetar Financial in an unrelated strategy to risk arbitrage, and they were obtained from prime brokers pursuant to customary securities lending agreements.

     

    Except as otherwise described herein, no contracts, arrangements, understandings or similar relationships exist with respect to the securities of the Company among or between the Reporting Persons or any other person or entity.

     

    ITEM 7.  MATERIAL TO BE FILED AS EXHIBITS
        
    Exhibit No.  Description

     

    99.1Joint Filing Agreement, dated as of February 8, 2021 among the Reporting Persons.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 8, 2021

     

     magnetar financial llc
       
     By:Magnetar Capital Partners LP, its Sole Member
       
    By:/s/ Alec N. Litowitz

       Name:Alec N. Litowitz
     Title:Manager of Supernova Management LLC, the General Partner of Magnetar Capital Partners LP

     

      magnetar capital partners LP
         
    By:/s/ Alec N. Litowitz
       Name:Alec N. Litowitz
       Title:Manager of Supernova Management LLC, the General Partner of Magnetar Capital Partners LP

     

      supernova management llc
         
    By:/s/ Alec N. Litowitz
       Name:Alec N. Litowitz
       Title:Manager
         
      /s/ Alec N. Litowitz
      Alec N. Litowitz

     

     

     

     

    SCHEDULE A

     

    Funds

     

    Date Number of Shares Bought Price Per Share($) (1)(2)
    12/23/2020 79 81.53
    12/28/2020 92 82.25
    1/4/2021 354,510 93.21957(3)
    1/4/2021 36,778 94.15478(4)
    1/5/2021 105,498 94.29979(5)
    1/6/2021 2,100 94.52286(6)
    1/7/2021 6,373 94.51722(7)
    1/8/2021 46,738 94.30645(8)
    1/11/2021 28,704 94.34956(9)
    1/12/2021 27,322 94.50156(10)
    1/13/2021 29,000 94.48233(11)
    1/14/2021 317,326 94.47578(12)
    1/15/2021 21,937 94.46332(13)
    1/19/2021 14,916 94.47966(14)
    1/20/2021 30,059 94.44775(15)
    1/21/2021 34,789 94.53152(16)
    1/22/2021 29,132 94.53520(17)
    1/25/2021 5,100 94.49903(18)
    1/26/2021 38,355 94.54829(19)
    1/27/2021 78,709 93.48357(20)
    1/27/2021 16,891 94.40003(21)
    1/28/2021 65,721 93.11958(22)
    1/28/2021 6,422 93.87959(23)
    1/29/2021 10,917 93.40299(24)
    1/29/2021 35,783 94.17312(25)
    2/1/2021 20,033 93.91264(26)
    2/2/2021 16,653 93.77606(27)

     

    (1)Excludes commissions and other execution-related costs.

    (2) Upon request by the staff of the Securities and Exchange Commission, full information regarding the number of shares bought or sold (as the case may be) at each separate price will be provided.

    (3) Reflects a weighted average purchase price of $93.21957 per share, at prices ranging from $92.9164 to $93.91 per share.

    (4) Reflects a weighted average purchase price of $94.15478 per share, at prices ranging from $93.93 to $94.23 per share.

    (5) Reflects a weighted average purchase price of $94.29979 per share, at prices ranging from $93.57 to $94.55 per share.

    (6) Reflects a weighted average purchase price of $94.52286 per share, at prices ranging from $94.50 to $94.54 per share.

    (7) Reflects a weighted average purchase price of $94.51722 per share, at prices ranging from $94.41 to $94.55 per share.

     

     

     

     

    (8) Reflects a weighted average purchase price of $94.30645 per share, at prices ranging from $93.91 to $94.55 per share.

    (9) Reflects a weighted average purchase price of $94.34956 per share, at prices ranging from $94.91 to $94.55 per share.

    (10) Reflects a weighted average purchase price of $94.50156 per share, at prices ranging from $94.30 to $94.55 per share.

    (11) Reflects a weighted average purchase price of $94.48233 per share, at prices ranging from $94.36 to $94.55 per share.

    (12) Reflects a weighted average purchase price of $94.47578 per share, at prices ranging from $94.36 to $94.55 per share.

    (13) Reflects a weighted average purchase price of $94.46332 per share, at prices ranging from $94.35 to $94.55 per share.

    (14) Reflects a weighted average purchase price of $94.47966 per share, at prices ranging from $94.41 to $94.55 per share.

    (15) Reflects a weighted average purchase price of $94.44775 per share, at prices ranging from $94.385 to $94.54 per share.

    (16) Reflects a weighted average purchase price of $94.53152 per share, at prices ranging from $94.5315 to $94.54 per share.

    (17) Reflects a weighted average purchase price of $94.53520 per share, at prices ranging from $94.49 to $94.55 per share.

    (18) Reflects a weighted average purchase price of $94.49903 per share, at prices ranging from $94.405 to $94.55 per share.

    (19) Reflects a weighted average purchase price of $94.54829 per share, at prices ranging from $94.535 to $94.55 per share.

    (20) Reflects a weighted average purchase price of $93.48357 per share, at prices ranging from $93.03 to $94.03 per share.

    (21) Reflects a weighted average purchase price of $93.40003 per share, at prices ranging from $94.21 to $94.55 per share.

    (22) Reflects a weighted average purchase price of $93.11958 per share, at prices ranging from $92.63 to $93.54 per share.

    (23) Reflects a weighted average purchase price of $93.87959 per share, at prices ranging from $93.66 to $94.00 per share.

    (24) Reflects a weighted average purchase price of $93.40299 per share, at prices ranging from $92.88 to $93.88 per share.

    (25) Reflects a weighted average purchase price of $94.17312 per share, at prices ranging from $93.89 to $94.53 per share.

    (26) Reflects a weighted average purchase price of $93.91264 per share, at prices ranging from $93.60 to $94.36 per share.

    (27) Reflects a weighted average purchase price of $93.77606 per share, at prices ranging from $93.57 to $94.27 per share.

      

    Funds

     

    Date Number of Shares Sold Price Per Share($) (1)(2)
    12/22/2020 3,811 80.01729(3)
    12/23/2020 5,000 81.80559(4)
    12/28/2020 5,000 82.16585(5)
    12/30/2020 5,181 82.58460(6)
    12/31/2020 5,000 83.06760(7)
    1/8/2021 2,332 94.34601(8)
    2/1/2021 57 93.67

     

    (1)Excludes commissions and other execution-related costs.

    (2) Upon request by the staff of the Securities and Exchange Commission, full information regarding the number of shares bought or sold (as the case may be) at each separate price will be provided.

    (3) Reflects a weighted average sale price of $80.01729 per share, at prices ranging from $79.96 to $80.075 per share.

    (4) Reflects a weighted average sale price of $81.80559 per share, at prices ranging from $81.69 to $81.888 per share.

    (5) Reflects a weighted average sale price of $82.16585 per share, at prices ranging from $82.14 to $82.22 per share.

    (6) Reflects a weighted average sale price of $82.58460 per share, at prices ranging from $82.21 to $83.00 per share.

    (7) Reflects a weighted average sale price of $83.06760 per share, at prices ranging from $83.06 to $83.17 per share.

    (8) Reflects a weighted average sale price of $94.34601 per share, at prices ranging from $94.00 to $94.63 per share.

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit No.  Description
    99.1  Joint Filing Agreement, dated as of February 8, 2021, among the Reporting Persons.

     

     

     

    Get the next $MGLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MGLN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MGLN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Journey Venture Studio Appoints First Four Board Members

    Notable Seasoned Entrepreneurs Will Support Inaugural Founders-In-Residence Cohort and the Development of Future Disruptive Healthcare Startups in Phoenix PHOENIX, July 24, 2023 /PRNewswire-PRWeb/ -- The Journey Venture Studio announced today the appointment of the first four members to its board of directors. Each board member was sought out as a mission-aligned partner as the studio prepares to launch its first Founder in Residence Cohort. The first four board members include: Heidi Jannenga, WebPT Co-founder & Chief Clinical Officer Jason Wood, Managing Director with Morgan Stanley Investment Management's Next Level Fund Andy Lombard, CEO of Arizona Venture Development Corporation (AVC) J

    7/24/23 9:00:00 AM ET
    $CNC
    $MGLN
    Medical Specialities
    Health Care
    Hospital/Nursing Management

    Concerned Shareholders of Cano Health Nominate Highly Qualified, Independent Director Candidates and Propose Removal of Dr. Marlow Hernandez from Board for Cause

    Group Details the Case for Urgent Change at Cano Following an Extended Period of Underperformance, Failed Capital Allocation, and Extremely Poor Governance and Strategic Execution Urges Stockholders to WITHHOLD Support for Incumbent Directors as Parties Await a Resolution of Litigation to Compel Company to Reopen Window for Nominating Director Candidates and Making Proposals Elliot Cooperstone, Lewis Gold and Barry Sternlicht (collectively with certain of their affiliates, the "Group," "us" or "we"), who recently resigned as members of the Board of Directors (the "Board") of Cano Health, Inc. ("Cano" or the "Company") (NYSE:CANO), today announced that they have submitted a notice to the

    5/18/23 9:28:00 AM ET
    $BKD
    $CANO
    $CIVI
    Hospital/Nursing Management
    Health Care
    Medical/Nursing Services
    Oil & Gas Production

    Magellan Health Opens 24-hour Crisis Line for Individuals Impacted by Hurricane Ian

    Consultation and resources available at no cost to local community Magellan Health, Inc. today announced that it has opened a complimentary 24-hour crisis line for individuals impacted by the aftermath of Hurricane Ian. The toll-free number to access free, confidential consultation services is 1-800-327-7451. Magellan confidential consultation services are offered at no charge to the community to assist individuals as they work to cope with the feelings of fear, sadness, anger, or hopelessness related to these kinds of natural disasters. Crisis line callers may also seek information and guidance to other available resources, such as community-based support. Tip sheets with resources spe

    9/29/22 11:00:00 AM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    $MGLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Feld Peter A returned 2,374,798 units of Ordinary Common Stock to the company, closing all direct ownership in the company

    4 - MAGELLAN HEALTH INC (0000019411) (Issuer)

    1/4/22 5:43:07 PM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    SEC Form 4: Shulman Steven J returned 27,451 units of Ordinary Common Stock to the company, closing all direct ownership in the company

    4 - MAGELLAN HEALTH INC (0000019411) (Issuer)

    1/4/22 5:22:13 PM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    SEC Form 4: West Jeffrey N returned 25,692 units of Ordinary Common Stock to the company, closing all direct ownership in the company

    4 - MAGELLAN HEALTH INC (0000019411) (Issuer)

    1/4/22 5:23:35 PM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    $MGLN
    SEC Filings

    View All

    SEC Form 15-12B filed by Magellan Health, Inc.

    15-12B - MAGELLAN HEALTH INC (0000019411) (Filer)

    1/14/22 4:08:42 PM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    SEC Form S-8 POS filed by Magellan Health, Inc.

    S-8 POS - MAGELLAN HEALTH INC (0000019411) (Filer)

    1/4/22 4:54:57 PM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    SEC Form S-8 POS filed by Magellan Health, Inc.

    S-8 POS - MAGELLAN HEALTH INC (0000019411) (Filer)

    1/4/22 4:52:36 PM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    $MGLN
    Leadership Updates

    Live Leadership Updates

    View All

    The Journey Venture Studio Appoints First Four Board Members

    Notable Seasoned Entrepreneurs Will Support Inaugural Founders-In-Residence Cohort and the Development of Future Disruptive Healthcare Startups in Phoenix PHOENIX, July 24, 2023 /PRNewswire-PRWeb/ -- The Journey Venture Studio announced today the appointment of the first four members to its board of directors. Each board member was sought out as a mission-aligned partner as the studio prepares to launch its first Founder in Residence Cohort. The first four board members include: Heidi Jannenga, WebPT Co-founder & Chief Clinical Officer Jason Wood, Managing Director with Morgan Stanley Investment Management's Next Level Fund Andy Lombard, CEO of Arizona Venture Development Corporation (AVC) J

    7/24/23 9:00:00 AM ET
    $CNC
    $MGLN
    Medical Specialities
    Health Care
    Hospital/Nursing Management

    Magellan Health Appoints Tom Britt as Chief Information Officer

    Magellan Health, Inc. today announced it has appointed Tom Britt as chief information officer for Magellan Health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220808005111/en/Tom Britt (Photo: Business Wire) Britt will work closely with Magellan's executive leadership to create, develop and implement information technology strategy and digital solutions while leveraging best practices and delivering data-enhanced products and services through innovative technology platforms. "Tom is a strong leader with over 25 years of significant leadership experience in building innovative digital products and solutions while leading high

    8/8/22 6:30:00 AM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    Magellan Health Appoints Dr. Caroline Carney as President of Behavioral Health

      Magellan Health, Inc., one of the nation's leaders in behavioral health, today announced it has appointed Caroline Carney, MD, MSc, FAPM, CPHQ, as president of behavioral health for its subsidiary, Magellan Healthcare. In this key leadership role, Dr. Carney will advance Magellan Health's clinical mission and further position the company's significant leadership capabilities in behavioral health, including collaborative and integrated approaches that enhance member experience across the continuum of care. Dr. Carney will also continue in her role as chief medical officer of Magellan Health, leading the development and implementation of innovative, integrated clinical programs for custo

    2/3/22 4:36:00 PM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    $MGLN
    Financials

    Live finance-specific insights

    View All

    Magellan Health Reports Third Quarter 2021 Financial Results

    Magellan Health, Inc. (NASDAQ:MGLN) today announced financial results for the third quarter ended September 30, 2021, as summarized below:             Three Months Ended   Nine Months Ended Sept 30   Sept 30 (In millions, except per share amounts)           Continuing Operations     2021         2020     Chg     2021     2020   Chg Net revenue $   1,254.1     $   1,170.1     7.2 %   $ 3,636.5   $ 3,392.6   7.2 % Net (loss) income $   (0.1 )   $   (17.3 )   NM     $ 21.9   $ 28.7   -23.7 % Segment profit [1] $   38.

    11/5/21 6:30:00 AM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    Magellan Health Reports Second Quarter 2021 Financial Results

    Magellan Health, Inc. (NASDAQ:MGLN) today announced financial results for the second quarter ended June 30, 2021, as summarized below: Three Months Ended     Six Months Ended June 30     June 30 (In millions, except per share amounts)                         Continuing Operations     2021         2020   Chg         2021       2020   Chg Net revenue $   1,220.8     $   1,100.1   11.0 %   $   2,382.4   $   2,222.5   7.2 % Net income (loss) $   (6.5 )   $   47.1   -113.7 %   $   22.0   $   46.0   -52.1 % Segment profit [1]

    8/5/21 6:30:00 AM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    Magellan Health Reports 2020 Financial Results

    PHOENIX--(BUSINESS WIRE)--Magellan Health, Inc. (NASDAQ: MGLN) today announced financial results for the fourth quarter and the year ended December 31, 2020, as summarized below:   Three Months Ended Twelve Months Ended December 31 December 31 (In millions, except per share amounts) Continuing Operations 2020 2019 Chg 2020 2019 Chg Net revenue $ 1,185.0   $ 1,133.8 4.5 % $ 4,577.5 $ 4,565.6 0.3 % Net (loss) income $ (24.7 ) $ 9.5 NM   $ 4.0 $ 12.6 -67.9 % Segment profit [1] $ 11.3   $ 55.9 -79.8 % $ 14

    2/26/21 4:55:00 PM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    $MGLN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Magellan Health, Inc. (Amendment)

    SC 13D/A - MAGELLAN HEALTH INC (0000019411) (Subject)

    1/6/22 5:18:35 PM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13G filed by Magellan Health, Inc.

    SC 13G - MAGELLAN HEALTH INC (0000019411) (Subject)

    7/6/21 2:59:29 PM ET
    $MGLN
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13D/A filed by Magellan Health, Inc. (Amendment)

    SC 13D/A - MAGELLAN HEALTH INC (0000019411) (Subject)

    4/27/21 3:59:03 PM ET
    $MGLN
    Hospital/Nursing Management
    Health Care